Non-Fucosylated Anti-Human Th17 (AZ17) Therapeutic Antibody - Creative Biolabs
Book a Meeting

Non-Fucosylated Anti-Human Th17 (AZ17) Therapeutic Antibody (CAT#: BioBet-1600ZP) Datasheet

Target
Th17
Isotype
IgG
Description
ADCC-Enhanced anti-Th17 (AZ17) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Inflammatory Diseases
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Th17 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Th17
Full Name
RG1
Background
Th17 are a subset of T helper cells developmentally distinct from Th1 and Th2 lineages producing interleukin 17 (IL-17). Th17 cells play a role in adaptive immunity protecting the body against pathogens.
Alternative Names
Th17
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with PPP1R3A include Diabetes Mellitus, Noninsulin-Dependent and Diabetes Mellitus.
Related Pathways
Its related pathways are Activation of cAMP-Dependent PKA and Beta-Adrenergic Signaling.
Function
It seems to be PP1 as a sugar target subunit. PP1 plays an important role in cell division and participates in the regulation of glycogen metabolism, muscle contraction and protein synthesis. It plays an important role in glycogen synthesis, but it is not necessary for insulin to activate glycogen synthase (similar).
Post-translational modifications
1.Phosphorylation at Ser-46 by ISPK stimulates the dephosphorylation of glycogen synthase and phosphorylase kinase 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
AZ17
Host
Human
Species Reactivity
Human
Description
AZ17 is a product of ALLOZYNE's E. coli based CAESAR platform and is composed of two single chain variable antibody fragments (scFvs), and AZ17 is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo. AZ17 holds the promise of superior efficacy, safety and possibly even dosing convenience over currently marketed therapies for various autoimmune diseases.
Indication
Inflammatory Diseases

Inflammatory Diseases

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany